| ₹ crore | Q2 FY27 | Q2 FY26 | Change |
|---|---|---|---|
| Revenue | 115 | 107 | +7.5% |
| EBITDA | 10.7 | 8.0 | +33.4% |
| EBITDA margin | 9.3% | 7.5% | +1.8 pts |
| Profit before tax | 7.7 | 5.1 | +49.4% |
| Net profit | 5.3 | 2.8 | +86.4% |
| EPS | ₹0.60 | ₹0.32 | +87.5% |
Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.
| Tap a line for its trend | Currentlast 12M | FY26Mar 2026 | FY25Mar 2025 |
|---|
| 919 | — | — | |
| 134 | 136 | 119 | |
| 0.2 | 0.2 | 0.2 | |
| 8.1 | 8.1 | 14.1 | |
| 793 | — | — | |
| 486 | 467 | 438 | |
| — | +6.6% | — | |
| 68.5 | 62.2 | 52.6 | |
| 14.1% | 13.3% | 12.0% | |
| 48.8 | 43.0 | 34.1 | |
| 45.6 | 34.6 | 26.7 | |
| 9.4% | 7.4% | 6.1% | |
| ₹5.12 | ₹3.89 | ₹3.01 | |
| — | +29.1% | — | |
| — | 43.3 | 120 | |
| — | −28.5 | −14.2 | |
| 14.8 | 14.8 | 106 | |
From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.
In ₹ Crore except Per Share 12 Months Ending | FY25 31/03/2025 | FY26 31/03/2026 | Current/LTM TTM · last close | |
|---|---|---|---|---|
| Market Capitalization | — | — | 918.6 | |
| - Cash, Equiv & ST Investments | 118.7 | 135.6 | 134.0 | |
| + Minority Interest | 0.2 | 0.2 | 0.2 | |
| + Total Debt | 14.1 | 8.1 | 8.1 | |
| Enterprise Value | — | — | 792.7 | |
| Revenue | 438.5 | 467.3 | 486.2 | |
| Growth %, YoY | — | +6.6 | — | |
| EBITDA | 52.6 | 62.2 | 68.5 | |
| Margin % | 11.99 | 13.31 | 14.08 | |
| EBIT | 34.1 | 43.0 | 48.8 | |
| Net Income | 26.7 | 34.6 | 45.6 | |
| Margin % | 6.09 | 7.40 | 9.38 | |
| EPS, Adj (current shares) | 3.01 | 3.89 | 5.12 | |
| Growth %, YoY | — | +29.1 | — | |
| Cash from Operations | 120.0 | 43.3 | — | |
| Capital Expenditures | -14.2 | -28.5 | — | |
| Free Cash Flow | 105.9 | 14.8 | 14.8 | |
Prices at the 30 October 2026 close · figures from the company's filings with NSE
Borosil Scientific (NSE: BOROSCI) had a market capitalisation of ₹905 crore at the 30 October 2026 close (₹101.73 a share), a PE ratio of 19.9 on the last four quarters' profit and a price-to-book ratio of 2.00. In FY26 its consolidated net profit was ₹34.6 crore on revenue of ₹467 crore; in Q2 FY27 (July–September 2026) it was ₹5.3 crore, up 83.7% year on year. Its debt-to-equity ratio was 0.01 on 30 September 2026. Promoters held 68.27% of the shares on 30 September 2026.
Borosil Scientific's PE ratio is 19.9 at the 30 October 2026 close (₹101.73 a share): a market capitalisation of ₹905 crore divided by consolidated net profit of ₹45.6 crore over the last four quarters (Q3 FY26 to Q2 FY27). On FY26 net profit (₹34.6 crore) it is 26.1.
Borosil Scientific's debt-to-equity ratio was 0.01 on 30 September 2026: borrowings of ₹5.2 crore against total equity of ₹452 crore. A year earlier, on 30 September 2025, it was 0.02.
Borosil Scientific's net worth — shareholders' equity in its consolidated balance sheet — was ₹452 crore on 30 September 2026, up 11.7% from ₹404 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹905 crore at the 30 October 2026 close.
Borosil Scientific's price-to-book (PB) ratio is 2.00 at the 30 October 2026 close: a market capitalisation of ₹905 crore divided by shareholders' equity (book value) of ₹452 crore on 30 September 2026. That is a book value of ₹50.77 per share against a share price of ₹101.73.
In FY26, Borosil Scientific's return on equity (ROE) was 8.2% and its return on capital employed (ROCE) was 9.8%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities).
Borosil Scientific's book value per share was ₹50.77 on 30 September 2026: shareholders' equity of ₹452 crore divided by the 8.9 crore shares in issue, up 11.7% from ₹45.47 a year earlier. The share price at the 30 October 2026 close was ₹101.73.
Borosil Scientific's market capitalisation was ₹905 crore at the 30 October 2026 close: 8.9 crore shares at ₹101.73 each.
No. Borosil Scientific had borrowings of ₹5.2 crore on 30 September 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.01. Its cash and current investments were ₹135 crore, so it held net cash of ₹129 crore.
Borosil Scientific's basic earnings per share (EPS) were ₹3.89 in FY26, against ₹3.02 in FY25. Over the last four quarters (Q3 FY26 to Q2 FY27) they add up to ₹5.13.
Promoters held 68.27% of Borosil Scientific on 30 September 2026, unchanged from the previous quarter and up 0.46 percentage points from 67.81% a year earlier, according to the shareholding pattern filed with NSE.
In FY26, Borosil Scientific generated ₹43.3 crore of cash from operations and spent ₹28.5 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹14.8 crore. In FY25 it was ₹106 crore.
In FY26 (April 2025–March 2026), Borosil Scientific's consolidated net profit was ₹34.6 crore, up 29.1% from ₹26.8 crore in FY25, on revenue from operations of ₹467 crore (up 6.6%).
On 30 September 2026, Borosil Scientific's shares were held by promoters 68.27%, foreign portfolio investors (FII/FPI) 0.14%, domestic institutions (DII) 0.28% (including mutual funds at 0.01%) and retail and other non-institutional investors 31.31%. Over the year, FII holding was up 0.07 percentage points from 0.07% and DII holding was up 0.18 percentage points from 0.10%.
Borosil Scientific's latest results are for Q2 FY27 (July–September 2026), filed on 28 October 2026: consolidated net profit ₹5.3 crore, up 83.7% from ₹2.9 crore in Q2 FY26; revenue from operations ₹115 crore, up 7.5% year on year.
In FY26, Borosil Scientific earned net profit of ₹34.6 crore on revenue of ₹467 crore, against ₹28.7 crore on ₹397 crore for Sejal Glass. Borosil Scientific's operating margin was 9.2% (Sejal Glass 11.6%) and its return on equity 8.2% (Sejal Glass 30.4%). At the 30 October 2026 close, Borosil Scientific's market capitalisation was ₹905 crore against ₹882 crore for Sejal Glass, and its PE ratio on FY26 profit 26.1 against 30.7.
Borosil Scientific has reported Q2 FY27. Its next results, for Q3 FY27 (October–December 2026), are due by 14 February 2027 under SEBI's 45-day rule; the company notifies the board-meeting date at least two working days before.
On FY26 consolidated figures, against Sejal Glass: Borosil Scientific's operating margin of 9.2% is the lower of the two (Sejal Glass 11.6%; peer average 11.6%); its return on equity of 8.2% is the lower of the two (Sejal Glass 30.4%; peer average 30.4%).
At the 30 October 2026 closing prices, on FY26 net profit, Borosil Scientific's PE ratio is 26.1, the lower of the two: Sejal Glass 30.7, a peer average of 30.7. Each is the company's market capitalisation at that price divided by its FY26 net profit.
From Borosil Scientific's own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 30 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.